Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682029 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL30681928 | 0.86 | KEAP1 (0.49) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL4497318 | 0.86 | KEAP1 (0.49) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL16945099 | 0.83 | KMT2A (0.71) | ALDH1A1HSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL26617507 | 0.83 | KEAP1 (0.54) | ALDH1A1ALOX5HPGDHSD17B10RXFP1 | |
| SCHEMBL2532082 | 0.83 | KMT2A (0.71) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL28234137 | 0.83 | MEN1 (0.49) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL790264 | 0.83 | PRNP (0.53) | ALDH1A1CYP2C9PTGESALOX5HPGD | |
| SCHEMBL2314993 | 0.83 | DHODH (0.48) | ALDH1A1HPGDHSD17B10RXFP1KDM4E | |
| SCHEMBL790477 | 0.81 | PRNP (0.52) | ALDH1A1CYP2C9PTGESALOX5HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211990-A1 | BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-103601674-B | A kind of suppress dipeptides kininase compound and preparation method and purposes | ZHEJIANG UNIVERSITY (CN) | 2015-09-23 | — | — | CN | disclosed |
| CN-102532009-B | compound for inhibiting dipeptide kininase and preparation method and application thereof | UNIV ZHEJIANG | 2014-11-05 | — | — | CN | disclosed |
| CN-103601674-A | Compounds for inhibiting dipeptide kininase, preparation method and applications thereof | UNIV ZHEJIANG | 2014-02-26 | — | — | CN | disclosed |
| US-8288549-B2 | Glycine B antagonist | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-10-16 | — | — | US | disclosed |
| CN-102532009-A | Compound for inhibiting dipeptide kininase and preparation method and application thereof | UNIV ZHEJIANG | 2012-07-04 | — | — | CN | disclosed |
| US-20110190342-A1 | GLYCINE B ANTAGONIST | HENRICH MARKUS | 2011-08-04 | — | — | US | disclosed |
| EP-2350014-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010037533-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190342-A1 | GLYCINE B ANTAGONIST | GRIN2B, GLRB, GRIN2A | ALDH1A1 4071/4885CYP2C9 2926/4885PTGES 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.